Mobilization kinetics of peripheral blood progenitor cells after IAPVP-16 salvage chemotherapy plus G-CSF in lymphoproliferative disorders

被引:6
作者
Altés, A
López, R
Martino, R
Martinez, C
Cabezudo, E
Muñoz, L
Santamaría, A
Perea, G
Briones, J
Salar, A
Sureda, A
Brunet, S
Madoz, P
Sierra, J
机构
[1] Hosp Santa Creu & Sant Pau, Clin Hematol Div, Barcelona 08025, Spain
[2] Hosp Santa Creu & Sant Pau, Hemotherapy Serv, Barcelona 08025, Spain
[3] Autonomous Univ Barcelona, Inst Canc Res, Barcelona, Spain
关键词
PBPC mobilization; lymphoma; chemotherapy;
D O I
10.1038/sj.bmt.1702476
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
We have explored the efficacy of salvage chemotherapy combination, IAPVP-16 (ifosfamide 5 g/m(2) on day 1; VP-16 100 mg/m(2) on days 1-3; ara-C 1.2 g/m(2)/12 h on days 1 and 2; methylprednisolone 80 mg/m(2) on days 1-5) plus G-CSF for PBPC mobilization, This protocol was used in 45 patients with relapsed or refractory lymphoproliferative diseases who underwent 85 leukaphereses, Tn 41 patients >2 x 10(6)/kg CD34(+) cells were obtained after a median of two procedures. The median number of CD34(+) cells harvested was 3.2 x 10(6)/kg per apheresis and 8.4 x 10(6)/kg per patient. Seven of 10 patients who had failed previous mobilization attempts achieved more than 2 x 10(6) CD34(+) cells/kg in a maximum of three aphereses, A history of previous mobilization failure and a low platelet count (<150 x 10(9)/1) negatively influenced the CD34(+) cell yield in univariate and multivariate analyses. A good correlation was found between the circulating CD34(+) cells/mu l and the CD34(+) cells and CFU-GM in the leukaphereses products (r = 0.93 and r = 0.73, P < 0.001), and greater than or equal to 17 CD34(+) cells/mu l predicted the achievement of >2 x 10(6)/kg CD34(+) cells in a single leukapheresis in more than 90% of cases. IAPVP-16 plus G-CSF may be specially indicated in tandem transplantations or CD34(+) selection and in patients who have failed previous mobilization attempts.
引用
收藏
页码:127 / 132
页数:6
相关论文
共 24 条
[1]   CD34 counts to predict the adequate collection of peripheral blood progenitor cells [J].
Armitage, S ;
Hargreaves, R ;
Samson, D ;
Brennan, M ;
Kanfer, E ;
Navarrete, C .
BONE MARROW TRANSPLANTATION, 1997, 20 (07) :587-591
[2]  
Bender J G, 1992, J Hematother, V1, P329, DOI 10.1089/scd.1.1992.1.329
[3]   PERIPHERAL-BLOOD STEM-CELLS (PBSCS) COLLECTED AFTER RECOMBINANT GRANULOCYTE-COLONY-STIMULATING FACTOR (RHG-CSF) - AN ANALYSIS OF FACTORS CORRELATING WITH THE TEMPO OF ENGRAFTMENT AFTER TRANSPLANTATION [J].
BENSINGER, WI ;
LONGIN, K ;
APPELBAUM, F ;
ROWLEY, S ;
WEAVER, C ;
LILLEBY, K ;
GOOLEY, T ;
LYNCH, M ;
HIGANO, T ;
KLARNET, J ;
CHAUNCEY, T ;
STORB, R ;
BUCKNER, CD .
BRITISH JOURNAL OF HAEMATOLOGY, 1994, 87 (04) :825-831
[4]  
Díaz MA, 1999, HAEMATOLOGICA, V84, P32
[5]   Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF [J].
Engelhardt, M ;
Winkler, J ;
Waller, C ;
Lange, W ;
Mertelsmann, R ;
Henschler, R .
BONE MARROW TRANSPLANTATION, 1997, 19 (06) :529-537
[6]  
GARCIA J, 1983, BIOL CLIN HEMATOL, V5, P99
[7]   Blood and marrow transplantation activity in Europe 1995 [J].
Gratwohl, A ;
Hermans, J ;
Baldomero, H .
BONE MARROW TRANSPLANTATION, 1997, 19 (05) :407-419
[8]  
HAAS R, 1994, BLOOD, V83, P3787
[9]  
HAYNES A, 1995, BONE MARROW TRANSPL, V16, P359
[10]  
Koumakis G, 1996, BONE MARROW TRANSPL, V18, P1065